Philogen is pleased to invite you to an upcoming webinar on March 30, 2026, at 15:00 GMT | 16:00 CET.
To register, please click on the link below or contact us at [email protected] for further details.
us06web.zoom.us/webinar/regi…
29
Philogen is pleased to invite you to an upcoming webinar on November 20, 2025, at 15:00 GMT | 16:00 CET.
To register: us06web.zoom.us/webinar/regi…
41
We are pleased to invite you to a webinar with Prof. Dario Neri, taking place today, June 11, at 11:00 ET | 17:00 CET.
Please contact us at [email protected] or follow the link to register to the event.
us06web.zoom.us/webinar/regi…
51
Philochem AG announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, Bristol Myers Squibb Company, for a potential value of up to $1.35bn plus royalties.
linkedin.com/feed/update/urn…
54
Philogen is pleased to invite you to an upcoming webinar on April 2, 2025, at 15:00 GMT | 16:00 CET.
Click on the link to register or contact us at [email protected]
us06web.zoom.us/webinar/regi…
44
Philogen Completes Patient Enrollment of the Phase III FIBROSARC Trial in Soft Tissue Sarcoma
linkedin.com/posts/philogen_…
1
31
Philogen is pleased to invite you to a new webinar on December 9, 2024, at 15:00 GMT | 16:00 CET
Please contact us at [email protected] or register to the link us06web.zoom.us/webinar/regi…
43
The Board of Directors approves the net financial position of Philogen for the third quarter of 2024
linkedin.com/feed/update/urn…
1
41
Sun Pharma and Philogen enter into a global Exclusive Commercialization, License, and Supply Agreement for Commercializing the specialty product FIBROMUN
linkedin.com/posts/philogen_…
2
50
Philogen is pleased to invite you to a new webinar on October 1, 2024, at 15:00 GMT | 16:00 CET
Management will present the financial results and provide an update on the industrial programs.
Follow the link to register us06web.zoom.us/webinar/regi…
47
Philogen is delighted to invite you to attend a virtual briefing on April 3, 2024 (at 10:00 ET / 15:00 BST / 16:00 CET) to discuss the Company’s Full Year 2023 Results.
Follow the link below to register to the event or contact us at [email protected].
us06web.zoom.us/webinar/regi…
87
Pleased to announce that the Philogen FIBROSARC (NCT04650984) Phase III trial will continue as planned by the protocol following the review of efficacy and safety data in the pre-planned interim analysis by an Independent Data and Safety Monitoring Board.
linkedin.com/feed/update/urn…
97
Excited to announce that Philogen has received the Good Manufacturing Practice Certificate for its Production facility in Rosia (Siena, Italy) by Competent Authorities
linkedin.com/feed/update/urn…
1
88
Following the announcements of this morning, Philogen management is inviting you to a Webinar on December 5 at 15:00 GMT | 16:00 CET.
us06web.zoom.us/webinar/regi…
79
Please have a look at the latest article published on s24ore.it/NudmeS via @sole24ore about Nidlegy™ Phase 3 trial
1
80
Nidlegy™ Phase III PIVOTAL trial meets the study’s primary objective in patients with locally advanced fully resectable melanoma (Price Sensitive)
linkedin.com/feed/update/urn…
Philogen is delighted to share the Half Year 2023 Financial Results.
linkedin.com/feed/update/urn…
1
81
Phiogen is delighted to share the Half Year 2023 Financial Results.
The company will host a Webinar to present the results on 2 October 2023 at 10:00 ET / 15:00 BST / 16:00 CET.
Follow the link here shorturl.at/JM178 to register to the event or contact [email protected]
62
Delighted to invite you to our Webinar on 2 October 2023 to discuss the Company’s Half Year 2023 Results on 2 October 2023 at 10:00 ET / 15:00 BST / 16:00 CET.
Following the link below to register to the event:
us06web.zoom.us/webinar/regi…
50


